A case of synchronous squamous cell lung cancer and gastric cancer treated with nivolumab demonstrating a long-term relapse-free survival
Yuta Nakamuraa Yuichi Tokunagaa Kosuke Kamadaa Yukiko Takenob Kenji Umekib Junichi Kadotab
aDepartment of Respiratory Medicine, Shinbeppu Hospital
bDepartment of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine
A 76-year-old man was diagnosed with synchronous double-primary carcinomas, namely squamous cell lung cancer (cT4N3M1a,Stage IVA) and gastric cancer. As a first-line chemotherapy, carboplatin (CBDCA) and nab-paclitaxel (nab-PTX) were administrated. One month after the treatment, both cancers had progressed, so he received nivolumab as a second-line treatment. With this treatment, both cancers ameliorated. The treatment effect was maintained over 96 weeks of nivolumab therapy. Nivolumab therapy might therefore be an effective therapy for synchronous double-primary carcinomas.
Lung cancer Gastric cancer Nivolumab
Received 1 Oct 2019 / Accepted 6 Jan 2020
AJRS, 9(2): 113-117, 2020